The 2026 American Association of Clinical Endocrinology (AACE) annual meeting is quickly approaching. From April 22 through April 24, 2026, in Las Vegas, Nevada, the AACE 2026 Annual Meeting is three days packed with more than 80 sessions on topics including diabetes, obesity, nutrition, and more. 

Today, we have a rundown of the sessions featuring diabetes topics. Some descriptions were edited for clarity and brevity. These session times and dates are accurate as of March 12, 2026. Consult the AACE 2026 Annual Meeting schedule for the most up-to-date information. 

Wednesday, April 22

DSN Year in Review: Diabetes

  • 8:00 AM – 8:45 AM
  • Description: Key publications from the past year encompassing the DSN specialty area of diabetes will be presented in an engaging didactic format with a brief commentary for each article to provide context and potential impact on clinical practice. Randomized controlled trials from high impact journals will be presented.

Advances in Prediabetes and Diabetes Prevention

  • 11:30 AM – 12:15 PM
  • Description: This session will explore practical, case-based approaches to prediabetes management and diabetes prevention focused on the 2026 AACE Diabetes Algorithm. With the algorithm’s release planned for early 2026, this interactive session at the AACE Annual Meeting will provide real-world strategies and clinical pearls, focusing on the updated prediabetes algorithm section and its implications for diabetes prevention.

Global Perspectives on Diabetes and Obesity

  • 1:30 PM – 2:30 PM
  • Description: This interactive session will examine the epidemiology of diabetes and obesity in the United States and worldwide, highlight regional challenges and disparities, and discuss clinical and public health management strategies, incorporating perspectives from Pakistan, India, and Mexico.

AI’s Transformation in Diabetes Care

  • 1:30 PM – 2:30 PM
  • Description: This presentation explores the transformative potential of artificial intelligence (AI) in diabetes management. It highlights how machine learning algorithms, predictive analytics, and decision-support tools are reshaping clinical workflows, enhancing patient monitoring, and improving treatment outcomes in the inpatient and outpatient settings.
Thursday, April 23

Perioperative Management of Continuous Glucose Monitoring (CGM) and Automated Insulin Delivery (AID) Systems

  • 8:00 AM – 8:45 AM
  • Description: Participants will learn the current evidence for the use of CGM and AID systems specifically in the peri-operative setting. Participants will also learn about the different AID systems used with CGM devices, specific features of these AID systems, and strategies to optimize glycemic control in the peri-operative setting for patients planned to undergo procedures and surgeries.

Should CGM Be Used for Gestational Diabetes?

  • 8:00 AM – 8:45 AM
  • Description: Continuous glucose monitoring has demonstrated tremendous benefits outside of pregnancy and is now the standard of care in pregnancies with type 1 diabetes. However the evidence is conflicting in gestational diabetes. Questions also remain on the optimal time in pregnancy range. This engaging and lively debate will discuss the benefits and limitations of using CGM in gestational diabetes.

Early-Stage Type 1 Diabetes: Screening, Monitoring, Treatments and Future Directions (Alan J. Garber, MD Lectureship)

  • 9:00 AM – 10:00 AM
  • Description: The speaker will summarize the stages of type 1 diabetes and monitoring strategies for individuals with presymptomatic type 1 diabetes, including the cadence of recommended metabolic follow-up and care considerations, and more.

Where Are We With Weekly Insulin? The Pros and Cons

  • 11:15 AM – 12:00 PM
  • Description: Insulin icodec is approved for use in the European Union, Canada, Australia, Japan, and Switzerland, but not the US. There is another weekly insulin under development, insulin efsitora, and a Point/Counterpoint session on these therapies on the horizon would be a timely addition to the annual meeting program. One faculty member could have experience in the clinical trials with the weekly insulins, and another could give a view from the regulatory perspective.

AACE 2026 Algorithm for Management of Adults with Type 2 Diabetes

  • 3:30 PM – 4:15 PM
  • Description: This session will review the principles of the AACE Algorithm for Management of Adults with Type 2 Diabetes focusing on the key updates made in 2026 based on pivotal clinical trial results.

Clinical Outcomes Associated With Continuation Versus Discontinuation of Insulin Pump Therapy in Hospitalized Adults With Diabetes

  • 3:30 PM – 3:45 PM
  • Description: Continuation of personal insulin pump therapy during hospitalization was associated with improved inpatient glycemic control and a shorter length of stay compared with pump discontinuation.

Diabetic Ketoacidosis and Safety Outcomes with GLP-1 Agonists in Type 1 Diabetes

  • 3:45 PM – 4:00 PM
  • Description: This study evaluates the risk of diabetic ketoacidosis (DKA) and other safety concerns associated with glucagon-like peptide-1 (GLP-1) agonist therapy in patients with type 1 diabetes.

Insulin Pumps for Type 2 Diabetes

  • 4:30 PM – 5:15 PM
  • Description: This session will provide practical guidance for patient selection and through a series of cases will provide best practices for system initiation, education and ongoing follow-up to optimize time in range and patient outcomes.
Friday, April 24

Cell Therapies in T1DM: Are We Close to a Cure?

  • 8:00 AM – 8:45 AM
  • Description: Participants will learn about innovative strategies about generating replenishable βeta cells, cell delivery technologies, and immune modulation to build immune tolerance. Participants will be able to identify the differences between primary pancreatic islets and stem cell derived islets, safety and optimal functional capabilities of cell therapies, and potential economic challenges of large-scale, cost-efficient manufacturing for accessible and sustainable cell therapies.

Glucose Immersion Impairs Retinal Pigment Epithelium Regeneration and Elevates Mitochondrial Membrane Potential in a Diabetic Zebrafish Model

  • 8:30 AM – 8:45 AM
  • Description: Using a zebrafish glucose immersion model of type II diabetes, we show that hyperglycemia profoundly suppresses RPE regeneration at 2, 4, and 7 days post-injury (dpi) and elevates mitochondrial membrane potential under baseline diabetic conditions, with persistent disruption of RPE architecture detectable by immunohistochemistry.

Diabetes Technology Hands-On Skills Workshop

  • 9:00 AM – 12:00 PM
  • Description: In this hands-on workshop, participants will enhance their skills in using diabetes management devices and improve their interpretation of Continuous Glucose Monitoring (CGM) data.

Atypical Diabetes in Focus: Advances in the Pathophysiology and Management of Post-Transplant Diabetes (PTD) and Cystic Fibrosis–Related Diabetes (CFRD)

  • 10:15 AM – 11:00 AM
  • Description: The pathophysiology, diagnosis, management, and prognosis of Post-Transplant Diabetes (PTD) and Cystic Fibrosis–Related Diabetes (CFRD) have significantly evolved over the past five years. Despite these advances, care for individuals with these atypical forms of diabetes remains suboptimal, largely due to limited resources and a shortage of providers with expertise in their management.

Sign up for alerts and stay informed on the latest clinical guidelines and guideline updates.

Copyright © 2026 Guideline Central, all rights reserved.